Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

t of SEGA response rate, with 35% of patients (27 of 78) receiving everolimus experiencing a 50% or greater reduction in SEGA volume (sum of volumes of all target SEGAs) relative to baseline versus 0% of patients (0 of 39) on placebo (p<0.0001)(1).

"This study, which included SEGA patients from infancy to adulthood, provides compelling evidence of the impact of everolimus in reducing SEGA size with a tolerability profile consistent with the previous everolimus trial in this treatment setting," said Dr. Sergiusz Jozwiak, a lead EXIST-1 investigator and Professor, Department of Child Neurology, The Children's Memorial Health Institute, Warsaw, Poland. "This is very good news for patients and caregivers in many countries who currently may face brain surgery as the only treatment option for growing SEGAs."

Everolimus targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism(9). Tuberous sclerosis complex is caused by defects in the TSC1 and/or TSC2 genes. When these genes are defective, mTOR activity is increased, which can cause uncontrolled tumor cell growth and proliferation, blood vessel growth and altered cellular metabolism, leading to the formation of non-cancerous tumors throughout the body, including the brain. By inhibiting mTOR activity in this signaling pathway, everolimus may reduce cell proliferation, blood vessel growth and glucose uptake related to SEGA associated with TSC(2,6).

"The positive results seen in the Phase III trial point to the important role of everolimus and mTOR inhibition in SEGA associated with TSC," said Herve Hoppenot, President, Novartis Oncology. "This outcome is welcome news as we continue our research efforts to fully understand the potential of this important treatment option across the wide range of disorders associated with TSC."

The Phase III study supports the findings of the Phase II study used for registration in s
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- Decision Resources Group finds that the laparoscopic device market ... increase to a value of over $4.3 billion by ... the large direct energy device market. In particular, premium-priced ... to the advantages they offer and as new products ... Resources Group,s coverage of the U.S. laparoscopic device market: ...
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
(Date:12/17/2014)... 2014 Revenue and earnings above the ... and development In the past 2013/14 fiscal year ... percent to EUR 4.287 billion (last year: EUR 4.190 billion) ... to EUR 360 million. "Overall, 2013/14 was a successful fiscal ... , President and CEO of Carl Zeiss AG. "Thanks to ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
(Date:12/20/2014)... 2014 The aftermath of the November 24th ... not only in Hollywood, but worldwide. As reported ... ripples of that attack are starting a finger-pointing game which ... But they are not the only ones affected, regular ... for some embarrassing times ahead, agents and lawyers could be ...
(Date:12/20/2014)... 2014 Parker & Sons, Inc. a ... of experience in contractor services announces reaching a milestone ... the homeowners of Arizona. Parker and Sons is comprised ... technicians that make customer service the number one priority. ... and started with one service vehicle and has since ...
(Date:12/19/2014)... Sarasota, Florida (PRWEB) December 19, 2014 Sub ... Bank to sponsor a blood drive Sunday the 28th from ... Clark Road & Sawyer Road in Sarasota, FL. , Inquiries ... special thank you for participating in the donating process, Sub ... a free flash frozen, custom ice cream. , About Sub ...
(Date:12/19/2014)... 2014 Eufaula, Oklahoma, located just 9 ... the state’s largest lake with more than 600 miles ... to a little more than 3,000 residents, hosted its ... the 6th of December. , Featuring Santa, Christmas lights ... Eufaula on Main Street. Narconon Arrowhead’s parade float ...
(Date:12/19/2014)... (HealthDay News) -- New research warns parents that buying an older ... Nearly half of teen drivers killed in the United States ... 11 years old and often lacked important safety features that are ... teen drivers killed in crashes were in cars at least six ... old, 31 percent were in cars 11 to 15 years old, ...
Breaking Medicine News(10 mins):Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Older Cars a Bad Choice for Younger Drivers 2
... new study shows patients who undergo chemotherapy or radiation expect ... from // chemotherapy or radiation can diminish the quality ... side effect, such as nausea, he or she is more ... gender, educational background, and the type of cancer influence how ...
... Patients with rheumatoid arthritis who receive a more intensive ... remission of their disease, finds a new study.// ... patients with similar levels of disease to one of ... drugs to fight rheumatoid arthritis, along with steroid injections. ...
... vertigo affects about 64 people in every 100,000. It is ... as often in women.// Simple exercises performed at home may ... a new study. ,Researchers studied 70 patients who had ... the inner ear canal. Participants reported experiencing episodes of nausea ...
... recent survey by the Centers for Disease Control and Prevention ... above the 85th percentile,// and 15 percent of children have ... the last 20 years and the National Institutes of Health ... overweight adults, which keeps them at high risk for heart ...
... done to activate the cells to destroy tumors. Researchers say ... may be due to different cell priming or suppressing mechanisms. ... method to activate the anti-cancer cells in mice. For the ... separated the anti-cancer cells. The cells were stimulated to become ...
... study shows soy protein with isoflavones does not have ... or cholesterol in postmenopausal women.// ,Researchers say ... related to a decrease in bone mineral density and ... women have taken hormone therapy to offset these effects ...
Cached Medicine News:
All Day Comfort for the Upper Body...
All Purpose, General Procedure Apron...
Designed to fit the body and priced to fit the budget! The Economy Tie apron has a belt that wraps around the body and ties in the front. Don't let the price fool you.... this apron provides the same...
This aron protects at 0.5 mm Pb equivalency and is 20% lighter than our Standard Back-Aid Apron - yet it contains no lead products that can be harmful to the environment!...
Medicine Products: